Horizon Therapeutics to make blockbuster out of Genmab drug in 2021
Tepezza can already boast one of the best launches ever for a rare disease drug, and current owner company Horizon Therapeutics forecasts that the drug, developed in Genmab's labs, will sell for more than a billion US dollars in 2021.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
US-based biopharmaceutical company Horizon Therapeutics is pulling out the big guns to market its rare disease drug, Tepezza, originally developed in the laboratories of Danish biotech firm Genmab.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab CEO: Three products may turn into five this year
For subscribers
Genmab CEO: Arbitration might be concluded in 2021
For subscribers
